Wixela Incurred, a combination inhaler containing fluticasone furoate and vilanterol, is not currently available in generic form. The drug is manufactured by GlaxoSmithKline (GSK) and was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the long-term maintenance treatment of asthma in patients aged 12 years and older [1].
When might a generic Wixela become available?
The availability of generic versions of Wixela Incurred is tied to the patent and exclusivity protections for the branded drug. Patents and regulatory exclusivities can prevent generic competition for a period after a drug's approval [2]. DrugPatentWatch.com tracks these intellectual property protections, which are crucial for determining when generic entry is possible [3]. Information on the specific patent expiry dates and any associated legal challenges would need to be consulted to estimate a potential generic launch timeline.
What is Wixela Incurred used for?
Wixela Incurred is prescribed to manage asthma in individuals aged 12 and above who require a long-term control medication. It is not intended for use as a rescue inhaler for acute asthma attacks [1]. The medication works by delivering two active ingredients: fluticasone furoate, an inhaled corticosteroid that reduces inflammation in the airways, and vilanterol, a long-acting beta2-adrenergic agonist (LABA) that helps to keep the airways open [1][4].
How does Wixela Incurred work?
The fluticasone furoate component of Wixela Incurred suppresses the inflammatory response in the lungs, which is a key factor in asthma. By reducing airway inflammation, it helps to prevent asthma symptoms from occurring. The vilanterol component acts as a bronchodilator, relaxing the muscles around the airways to improve airflow. The combination of these two mechanisms provides long-term control of asthma symptoms [1][4].
What are the risks or side effects of Wixela Incurred?
Like all medications, Wixela Incurred carries potential risks and side effects. Common side effects reported include upper respiratory tract infections, pneumonia, oral thrush, hoarseness, and headaches. Patients are advised to rinse their mouths with water after using the inhaler to reduce the risk of oral thrush [1]. Serious side effects can include paradoxical bronchospasm, worsening of asthma, and effects related to the corticosteroid component, such as decreased bone mineral density and ocular changes. The LABA component carries warnings about an increased risk of asthma-related hospitalization and death when used alone in patients with asthma, though this risk is mitigated when used in combination with an inhaled corticosteroid like fluticasone furoate [1][4].
Are there alternative treatments for asthma?
Yes, there are several alternative treatment options for asthma, depending on the severity and individual patient needs. These include other inhaled corticosteroids, long-acting beta2-agonists (used in combination with inhaled corticosteroids), short-acting beta2-agonists for quick relief, leukotriene modifiers, and biologics for severe asthma [4]. The choice of treatment is determined by a healthcare provider based on a comprehensive assessment of the patient's condition.